PRO-140 Progenies

IDrugs

Volumn 4, Issue 9, 2001, Pages 1068-1071

  Poli, Guido ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0042896001     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. 211441 Report by Progenies and ADARC on discovery of HIV second receptor. Progenies Pharmaceuticals Ine PRESS RELEASE 1996 June 19 •• Identification of CCR5 chemoklne receptor as co-receptor of non-syncitium-inducing HIV strains. (See [286246], [286247]).
2. 268407 Progenies Pharmaceuticals awarded $3.0 million from the National Institutes of Health for HIV program. Progenies Pharmaceuticals Inc PRESS RELEASE 1997 November 04
3. 273391 Progenies Pharmaceuticals and ADARC identify HIV binding site on CCR5 co-receptor; Results published in the Journal of Virology. Progenies Pharmaceuticals Inc PRESS RELEASE 1998 January 05 Announcement of the publication of a paper in Journal of Virology (See [421256]), reporting the identification of a binding site for HIV on the CCR5 co-receptor. The finding was the result of a collaboration between scientists from the Aaron Diamond AIDS Research Center (ADARC) and Progenies.
4. 281400 Progenies Pharmaceuticals1 HIV products show promising results in phase l/ll clinical trials - results presented at keystone symposium on HIV pathogènes and treatment. Progenies Pharmaceuticals Ine PRESS RELEASE 1998 March 17 •• March 1993 press release on the automated ProSys assay that detects HIV fusion with target cells without using infectious virus. Pro-542 is a recombinant CD4-lgG2 that inhibits attachment of HIV virions to the target cells.
5. 286246 Identification of a major co-receptor for primary isolates of HIV-1. Deng H et al NATURE 1996 381 661 - 666 Identification of CCR5 as a co-receptor for M-tropic virus to enter cells.
6. 286247 HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Dragic T et al NATURE 1996 381 667 - 673 Identification of CCR5 as a co-receptor for M-tropic virus to enter cells.
7. 306909 Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Liu R, Paxton W A, Choe S, Ceradini D, Martin S R, Horuk R et al CELL 1996 86 367 - 377
8. 313494 Progenies identifies novel HIV product and presents PRO 542 clinical results; new HIV discovery research and PRO 542 clinical trial results presented. Progenies Pharmaceuticals Inc PRESS RELEASE 1999 February 03
9. 322637 Progenies report on novel HIV inhibitor is published in the Journal of Virology. Progenies Pharmaceuticals Inc PRESS RELEASE 1999 April 26 •• Identification of PRO-140 (PA14) muring anti-CCRS IgGI monoclonal antibody (see [421264]).
10. 325445 Protein Design Labs and Progenies Pharmaceuticals announce humanization agreement for anti-CCRS antibody. Protein Design Labs Inc PRESS RELEASE 1999 May 19 • Collaboration with Protein Design Lab to carry out the humanization of PRO-140.
11. 342173 New studies show Progenies drug to be potent HIV inhibitor. Progenies Pharmaceuticals Inc PRESS RELEASE 1999 October 05
12. 361819 Progenies reports progress on HIV therapies - findings advance the development of novel agents which block HIV infection. Progenies Pharmaceuticals Ine PRESS RELEASE2000 April 06
13. 365216 Progenies Pharmaceuticals Inc reports first quarter 2000 results Progenies Pharmaceuticals Ine PRESS RELEASE 2000 May 04 April 2000 press release: Progenies expected to commence phase l/ll trials with PRO-140.
14. 375598 Progenies announces publication of encouraging clinical results with HIV drug. Progenfcs Pharmaceuticals Inc PRESS RELEASE2000 Jury 20
15. 330352 Comparative and combinatorial analysis of the HfV-1 entry inhibitors PRO 542, T-20 and PRO 140. Olson W, Nagashima K, Rosenfield S, Maddon P INT CONFAIDS 2000 2 WeOrA533 • PRO-140 inhibits HIV replication in synergy with other entry inhibitors such as PRO-542 and T-20
16. 382628 Progenies reports new triple drug cocktail potently blocks HIV. Progenies Pharmaceuticals Inc PRESS RELEASE2OOO September 18 Report of the synergisSc effect of combinations of PRO-542 + T-20 + PRO-140.
17. 385982 Progenies awarded $6.0 million for HIV therapy and vaccine programs. Progenies Pharmaceuticals Inc PRESS RELE4SE2000 October 17
18. 386699 Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Olson WC, Rabut GEE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Quo Y, Moore JP, Maddon PJ J VIROL 1999 73 4145 - 4155 •• Novel antibodies with anti HIV-1 entry and fusion activities. Description of three-stage HIV-1 entry model.
19. 393202 Progenies' HIV therapies featured at scientific conference. Progenies Pharmaceuticals Inc PRESS RELEASE 2000 December 11
20. 395621 Progenies reports publication of encouraging antiviral studies of novel HIV therapy PRO 140. Progenies Pharmaceuticals Inc PRESS RELEASE 2001 January 09 •• PRO-140 has a broad spectrum activity against the replication of primary HIV isolates obtained from infected individuals in primary cells (see [396968]).
21. 396968 Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. Trkda A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC J VIROL 2001 75 2 579 - 588 •• Description of a novel antibody directed to CCR5 with anti-HIV activity.
22. 398168 Progenies to develop new AIDS drug to inhibit viral entry and infection; lead candidate selected: - in preclinical studies with another 'entry inhibitor,' HIV showed no signs of drug resistance. Progenies Pharmaceuticals Inc PRESS RELEASE 2001 February 07 • Press release indicating lack of drug resistance with PRO-140 after 40 weeks of treatment.
23. 401628 Mechanisms of synergy between HIV-1 attachment, coreceptor and fusion inhibitors. Nagashima K, Rosenfield S, Thompson 6, Maddon P, Dragic T, Olson W INT CONF RETROVIRUSES OPPORTUNISTIC INFECT 2001 8 February 4-8 310 •• PRO-140 inhibits HIV replication in synergy with other entry inhibitors such as PRO-542 and T-20.
24. 404945 Progenies' experimental drug, PRO 140, lowered viral loads to undetectable levels in animal model of HIV infection: monoclonal antibody inhibited replication of HIV in vivo by blocking viral entry. Progenies Pharmaceuticals Ino PRESS RELEASE 2001 April 09 •• April 2001 press release: potent suppression of HIV replication in SCID-Hu mouse model of HIV infection with a single dose of PRO-140.
25. 406871 Potent in vivo suppression of HIV-1 replication with single-dose PRO 140, a novel inhibitor of CCRS-mediated viral entry. O'Hara BM, Franti M, Olson WC, Nagashima KA, Burton DR, Maddon PJ, Poignard P ANTIVIRAL RES 2001 50 1 LB-2 • Potent suppression of HIV replication in SCID-Hu mouse model of HIV infection with a single dose of PRO-140.
26. 408483 Progenies' experimental drug reduces brain damage when given three hours after stroke in animal model - novel antioxidant readily crosses blood-brain barrier.' Progenies Pharmaceuticals Inc PRESS RELEASE 2001 May 09 May 2001 press release: PRO-140 is preparing to commence phase l/ll trials.
27. 409142 Progenies Pharmaceuticals reports first quarter 2001 results. Progenies Pharmaceuticals Inc PRESS RELEASE2001 May 15
28. 419923 Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. Connor Rl, Sheridan KE, Ceradini D, Choe S, Landau NR J EXP MED 1997185 621 - 628
29. 419924 Genetic effects on HIV disease progression, loannidis JPA, O'Brien TR, Rosenberg PS, Contopoulos IDG, Goedert JJ NAT MED 1998 4 536
30. 419925 CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4T cells: role of signal transduction. Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, Arthos J, Olivia A, Ehler L, Mizell S, Jackson R et al PROC NATL ACAD SCI U S A 199895 1188011885
31. 421256 Ammo-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. Dragic T, Trkola A, Un SW, Nagashima KA, Kajumo F, Zhao L, Olson WC, WuL, Mackay CR, Allaway GP, Sakmar TP et alJ VIROL 199872 1 279 - 285
32. 421264 Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. Olson WC, Rabut GEE, Nagashima KA, Tran DNH, Anselma DJ, Monard SP, Segal JP, Thompson DAD, Kajumo F, Quo Y, Moore JP et al J VIROL 1999 73 5 4145 - 4155